The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.
April 17th 2024
This analysis looked at the potential connection between SARS-CoV-2 test positivity and new asthma diagnoses.
For patients with seasonal allergies the prescription medications available may not be enough to help with their symptoms and shots may not be an option they want to consider. Newly developed sublingual immunotherapies have been developed to help these patients manage their daily lives.
Q&A With Bryan Martin From The Ohio State University: ACAAI Aims To Move Field Into The Future
The world of medicine is changing and because of that organizations need to change as well. The American College of Allergy, Asthma, & Immunology is no exception to that trend.
Tiotropium Inhaler Add-On Improves Lung Function in Young Asthmatic Patients
November 8th 2015Even with the combination of inhaled corticosteroids (ICS) and long-acting beta agonists (LABAs), about 46% of young patients still suffer from poorly controlled asthma. A new analysis found that an add-on inhaler may be just what patients need to reach improved lung function.
Adherence to Omalizumab Does Not Correlate with Better Response for Asthma
November 8th 2015While clinicians should always encourage their patients to follow their medication schedules, it proved not to be a significant factor in the outcomes in patients with asthma taking omalizumab, according to a poster session at the 2015 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting (ACAAI 2015) in San Antonio, Texas.
For patients with severe seasonal allergies the regularly available medications may not be enough to help their symptoms while the prospect of shots may be prohibitive enough to keep them from getting shots. A newly approved treatment could provide an alternative to the needle.
Asthma in Review: What Have We Learned This Past Year?
November 6th 2015A presentation at the 2015 ACAAI Annual Meeting reviewed several key developments in the world of asthma that were published within the past year. The four main takeaways touched on the inhalant SB010, severe refractory asthma, medication during pregnancy, and the use of tiotropium.
Q&A With Daniel Ouellette From Henry Ford Hospital: Benefits Seen In Raising Smoking Age To 21
With the federal government leaving it to state and local entities to determine the age at which tobacco products can be purchased, an effort is underway to advance the age limit three years to 21.
Kids with Asthma Who Are Allergic to Milk Should Still Receive Immunotherapy
Although asthma increases the risk of anaphylaxis in children with milk allergies and reduces the chance that immunotherapy will prove fully successful, study results show that the majority of patients who undergo immunotherapy for a milk allergy can achieve a protective dose.
Pollution from Automobiles Contributes to Respiratory Disease in Children
Hospital admissions increase for children with respiratory illnesses due to particles emitted by vehicles, according to findings published in the Journal of the Air & Waste Management Association.
Many States Now Require Schools to Stock Epinephrine Autoinjectors
Over the past year, school officials in several of the nation's largest states have implemented new policies to address the growing prevalence and severity of pediatric allergies by increasing access to epinephrine auto-injectors.
Pulmonology Crisis: Wildfires Have the West Wheezing
Firefighters aren't the only heroes coping with wildfires in the Western US. The record-setting blazes are sending droves of patients with breathing problems to hospitals and clinics seeking help from pulmonologists.
Omalizumab Highly Effective for Treatment of Chronic Spontaneous Urticaria
A study in Drug Design, Development, and Therapy provides further evidence that omalizumab is safe and effective for treatment of chronic spontaneous urticaria (CSU). Omalizumab is currently used to treat adult and pediatric patients with asthma and is FDA-approved for use in patients with CSU refractory to antihistamines. These results further outline the effectiveness of the drug in treating CSU and suggest a bump for omalizumab in the typical treatment protocol for CSU.